Morgan Stanley Caribou Biosciences, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,749,597 shares of CRBU stock, worth $3.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,749,597

Previous 1,198,165 129.48%

Holding current value

$3.71 Million

Previous $2.34 Million 87.11%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.59 - $2.79 $2.47 Million - $4.33 Million	1,551,432 Added 129.48%	2,749,597 $4.37 Million
Q3 2024 Nov 14, 2024	BUY	$1.56 - $2.73 $904,297 - $1.58 Million	579,678 Added 93.73%	1,198,165 $2.34 Million
Q2 2024 Oct 17, 2024	BUY	$1.62 - $5.05 $330,463 - $1.03 Million	203,990 Added 49.21%	618,487 $1.01 Million
Q2 2024 Aug 14, 2024	BUY	$1.62 - $5.05 $330,463 - $1.03 Million	203,990 Added 49.21%	618,487 $1.01 Million
Q1 2024 Oct 17, 2024	SELL	$4.82 - $8.26 $983,231 - $1.68 Million	-203,990 Reduced 32.98%	414,497 $2.13 Million
Q1 2024 Aug 16, 2024	SELL	$4.82 - $8.26 $3.33 Million - $5.7 Million	-690,316 Reduced 62.48%	414,497 $2.13 Million
Q1 2024 May 15, 2024	SELL	$4.82 - $8.26 $3.33 Million - $5.7 Million	-690,316 Reduced 62.48%	414,497 $2.13 Million
Q4 2023 Aug 16, 2024	BUY	$3.58 - $6.25 $1.74 Million - $3.04 Million	486,326 Added 78.63%	1,104,813 $6.33 Million
Q4 2023 Feb 13, 2024	SELL	$3.58 - $6.25 $2.55 Million - $4.46 Million	-712,866 Reduced 39.22%	1,104,813 $6.33 Million
Q3 2023 Nov 15, 2023	BUY	$4.08 - $8.14 $2.25 Million - $4.48 Million	550,946 Added 43.49%	1,817,679 $8.69 Million
Q2 2023 Aug 14, 2023	BUY	$4.04 - $5.47 $70,639 - $95,642	17,485 Added 1.4%	1,266,733 $5.38 Million
Q1 2023 May 15, 2023	BUY	$4.3 - $7.78 $86,348 - $156,230	20,081 Added 1.63%	1,249,248 $6.63 Million
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $81,182 - $160,470	14,575 Added 1.2%	1,229,167 $7.72 Million
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $3.05 Million - $7.31 Million	571,409 Added 88.84%	1,214,592 $12.8 Million
Q2 2022 Oct 27, 2022	BUY	$5.1 - $9.74 $2.25 Million - $4.29 Million	440,295 Added 217.01%	643,183 $3.49 Million
Q2 2022 Aug 15, 2022	BUY	$5.1 - $9.74 $2.25 Million - $4.29 Million	440,295 Added 217.01%	643,183 $3.49 Million
Q1 2022 Oct 27, 2022	SELL	$8.42 - $15.32 $3.71 Million - $6.75 Million	-440,295 Reduced 68.46%	202,888 $1.86 Million
Q1 2022 May 13, 2022	BUY	$8.42 - $15.32 $840,484 - $1.53 Million	99,820 Added 96.85%	202,888 $1.86 Million
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $734,052 - $1.17 Million	50,312 Added 95.37%	103,068 $1.56 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $830,907 - $1.6 Million	52,756 New	52,756 $1.26 Million

Others Institutions Holding CRBU

# of Institutions

137

Shares Held

54.3M

Call Options Held

21.2K

Put Options Held

96.4K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $82.1M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account